Tucatinib, sold under the brand name Tukysa, is an anticancer medication used to treat HER2 positive breast cancer. It works as a small molecule inhibitor of HER2, blocking the enzyme that drives the growth of these cancer cells. Developed by Array BioPharma, it is taken orally, usually in combination with other therapies. The drug received United States approval in April 2020, followed by approval in Australia in August 2020 and in the European Union in February 2021.
Facts
Drug ClassSmall molecule HER2 kinase inhibitor 1 Mechanism of ActionBlocks the HER2 kinase enzyme, preventing HER2-positive cancer cells from growing 1 Approved UseIndicated with trastuzumab and capecitabine for advanced unresectable or metastatic HER2-positive breast cancer 1 First Approved / Isolated Year Significant RiskCommon side effects include diarrhea, palmar-plantar erythrodysesthesia, nausea, fatigue, hepatotoxicity, vomiting and stomatitis 1 Classification
Approval Status ATC ClassSourced to the subject's own accountL: Antineoplastic and Immunomodulating Agents 2 Route of Administration Connections
Sources
1. Tucatinib (Wikipedia)
Lead section
Small molecule inhibitor of HER2
History section
Kinase inhibitor meaning it blocks a type of enzyme (kinase) and helps prevent the cancer cells from growing
Medical uses section
Indicated in combination with trastuzumab and capecitabine for the treatment of adults with advanced unresectable or metastatic HER2-positive breast cancer
History section, FDA approval sentence
In April 2020, the U.S. Food and Drug Administration (FDA) approved tucatinib
Lead section, side effects sentence
Common side effects include diarrhea, palmar-plantar erythrodysesthesia (burning or tingling discomfort in the hands and feet), nausea, fatigue, hepatotoxicity (liver damage), vomiting, stomatitis (inflammation of the mouth and lips)
Lead section, approval-status statement
Tucatinib was approved for medical use in the United States in April 2020, in Australia in August 2020, and in the European Union in February 2021.
View the Source2. Anatomical Therapeutic Chemical Classification System (Wikipedia)
WikipediaFirst-level anatomical group codes, Code LQuote, First-level anatomical group codes, Code L
Antineoplastic and immunomodulating agents
3. Tucatinib (Wikipedia)
WikipediaInfobox drug, routes_of_administrationQuote, Infobox drug, routes_of_administration
By mouth
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.